These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1026705)

  • 41. Twenty-four-hour single-container system for parenteral nutrient admixtures.
    Raebel MA; McDonald JB
    Am J Hosp Pharm; 1985 Jun; 42(6):1355-8. PubMed ID: 3925769
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plastic containers for intravenous solutions.
    Med Lett Drugs Ther; 1975 May; 17(10):43-4. PubMed ID: 1128439
    [No Abstract]   [Full Text] [Related]  

  • 43. A cost comparison of intramuscular versus intravenous imipenem.
    Chin A; Gill MA; Ito MK; Yellin AE; Berne TV; Heseltine PN; Appleman MD
    Hosp Pharm; 1989 Nov; 24(11):905-9. PubMed ID: 10296145
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Antibiotic prophylaxis in gastrointestinal surgery. Peroral preparations are often better and cheaper than intravenous prophylaxis].
    Rasmussen IC; Odenholt I; Raab Y
    Lakartidningen; 2000 Jun; 97(26-27):3156-8. PubMed ID: 10925573
    [No Abstract]   [Full Text] [Related]  

  • 45. Drug costs and evaluation of packaging economies.
    Woodell J; Whitten JR
    Am J Hosp Pharm; 1968 Jul; 25(7):367-9. PubMed ID: 5696157
    [No Abstract]   [Full Text] [Related]  

  • 46. Bacterial corneal ulcers.
    Wilhelmus KR
    Int Ophthalmol Clin; 1984; 24(2):1-16. PubMed ID: 6724819
    [No Abstract]   [Full Text] [Related]  

  • 47. Cost comparison of unit dose drug distribution for adult and pediatric medicine patients.
    Arrington DM; Derewicz HJ; Lamy PP
    Am J Hosp Pharm; 1974 Jun; 31(6):578-81. PubMed ID: 4407474
    [No Abstract]   [Full Text] [Related]  

  • 48. Cost of intravenous antibiotic therapy. Frequency of administration as a factor.
    Peterson CD; Rosborough TK
    Postgrad Med; 1983 Sep; 74(3):304-5. PubMed ID: 6889204
    [No Abstract]   [Full Text] [Related]  

  • 49. Cost comparison of seven antibiotic combinations as empiric therapy in a simulated febrile neutropenic patient.
    Parr MD; Waite WW; Hansen LA; McDaniel PA
    Am J Hosp Pharm; 1985 Nov; 42(11):2484-8. PubMed ID: 4073066
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Personnel costs and preparation time in a centralized intravenous admixture program.
    Ryan DM; Daniels CE; Somani SM
    Am J Hosp Pharm; 1986 May; 43(5):1222-5. PubMed ID: 3087164
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost analysis of three intravenous drug delivery systems in a neonatal intensive care unit.
    Yu YK; Ishisaka DY; Nishizaki TT; Lee-Ow AM; Oliver FC
    Am J Health Syst Pharm; 1996 Oct; 53(19):2314-8. PubMed ID: 8893071
    [No Abstract]   [Full Text] [Related]  

  • 52. Therapeutic availability of antibiotics in parenteral solutions.
    Bair JN; Carew DP
    Bull Parenter Drug Assoc; 1965; 19(6):153-63. PubMed ID: 5837809
    [No Abstract]   [Full Text] [Related]  

  • 53. Bacterial endophthalmitis: culture proven failure of combined systemic, periocular, and topical antibiotics.
    Mirate DJ; Hull DS; Bobo C
    Ann Ophthalmol; 1981 Dec; 13(12):1341-2. PubMed ID: 7337342
    [No Abstract]   [Full Text] [Related]  

  • 54. Economic implications of oral treatment replacing parenteral therapy in antimicrobial chemotherapy.
    Leigh DA
    Chemioterapia; 1988 Dec; 7(6):400-5. PubMed ID: 3219753
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of an antibiotic intravenous to oral sequential therapy program.
    Pablos AI; Escobar I; Albiñana S; Serrano O; Ferrari JM; Herreros de Tejada A
    Pharmacoepidemiol Drug Saf; 2005 Jan; 14(1):53-9. PubMed ID: 15534901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Vancomycin and teicoplanin use as antibiotic prophylaxis in cardiac surgery: pharmacoeconomic study].
    Codina C; Miró JM; Tuset M; Claramonte J; Gomar C; Gotsens R; Gómez B; Suárez S; Abellana R; Ascaso C; Cartaña R; Rodríguez E; Asenjo M; Carné X; Trilla A; Marco F; Gómez J; Brunet M; Pomar JL; Gatell JM; Ribas J
    Med Clin (Barc); 2000; 114 Suppl 3():54-61. PubMed ID: 10994565
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A cost comparison of intravenous cimetidine delivery systems.
    Jackson CW; Caldwell RD; Arford PD
    Hosp Pharm; 1990 Dec; 25(12):1085-9. PubMed ID: 10108250
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Economics of providing antineoplastic drugs in a manufacturer-mixed bulk package.
    Kleinberg ML; Duafala ME
    Am J Hosp Pharm; 1988 Jan; 45(1):109-15. PubMed ID: 3348222
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Contamination of intravenous solutions by airborne microbes.
    Hansen JS; Hepler CD
    Am J Hosp Pharm; 1973 Apr; 30(4):326-31. PubMed ID: 4697656
    [No Abstract]   [Full Text] [Related]  

  • 60. Number of serum drug concentration determinations influences costs of pharmacokinetic dosing programs.
    Millikan MD; Farnett LE
    Am J Hosp Pharm; 1987 Feb; 44(2):278, 282. PubMed ID: 3565381
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.